Why the study?
It was hypothesized that functional limitation assessed by the six-minute walking test would improve the accuracy of heart failure prognostic models incorporating natriuretic peptides.
Does severe functional impairment assessed by the 6-minute walking test predict 1-year all-cause mortality in patients with chronic heart failure?
Does severe functional impairment assessed by the 6-minute walking test predict 1-year all-cause mortality in patients with chronic heart failure?
Severe functional impairment assessed by the 6-minute walking test provides strong, incremental prognostic value for 1-year mortality beyond established risk markers and the MAGGIC score in heart failure patients.
Severe functional impairment may aid mortality risk stratification in chronic HF; extends multivariable models but requires prospective validation before guiding care.
Natriuretic peptides (NP) are recognized as the most powerful predictors of adverse outcomes in heart failure (HF). We hypothesized that a measure of functional limitation, as assessed by six-minute walking test (6MWT), would improve the accuracy of a prognostic model incorporating a NP. We studied the prognostic value of severe functional impairment (SFI), defined as the inability to perform a 6MWT or a distance walked during a 6MWT <300 m, in 1696 patients with HF admitted to cardiac rehabilitation. The primary outcome was 1-year all-cause mortality. After adjusting for the baseline multivariable risk model -including age, sex, systolic blood pressure, moderate-to-severe anemia, renal dysfunction, sodium level, and NT-proBNP- or for the MAGGIC score, SFI had an odds ratio of 2.58 (95% CI 1.72-3.88; p <.001) and 3.12 (95% CI 2.16-4.52; p<.001), respectively. Adding SFI to the baseline risk model or the MAGGIC score yielded a significant improvement in discrimination and risk classification, with the majority of the patients with events being reclassified upwards. Our data suggest that a simple, 6MWT-derived measure of SFI is a strong predictor of death and provide incremental prognostic information over well-established risk markers in HF, including a NP, and over the MAGGIC score.
No takes yet. Share an insight, caveat, or question.
Scrutinio et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: